BioMarin's Carnage Could Be Buying Opportunity, Says Stifel
February 16, 2016 at 11:06 AM EST
According to a recent research summary from Stifel, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is deserving of an ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.